Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Orthofix Medical Inc.
Report date December 31, 2022 · Filed January 11, 2023
Section 16 reporting ended · disclosed 2023-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,813 |
Reported balance
After 2022-10-31 transaction · row 1
1 source rowRow 1 · 2022-10-31 · Grant · Acquired 293 · Balance 37,813 F1: Shares purchased pursuant to the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan, as Amended (the "Stock Purchase Plan") for the plan period ended October 31, 2022. F2: Pursuant to the terms of the Stock Purchase Plan, shares are purchased at 85% of the fair market value of the Orthofix stock on the first day of the plan period or, if lower, on the last day of the plan period. Accordingly, shares were purchased at $13.65 per share, or at 85% of the quoted market price of $16.06 on October 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased pursuant to the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan, as Amended (the "Stock Purchase Plan") for the plan period ended October 31, 2022.
F2: Pursuant to the terms of the Stock Purchase Plan, shares are purchased at 85% of the fair market value of the Orthofix stock on the first day of the plan period or, if lower, on the last day of the plan period. Accordingly, shares were purchased at $13.65 per share, or at 85% of the quoted market price of $16.06 on October 31, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2022 Filed Jan 11, 2023 21:50 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 293 | $13.65 | $3,999.45 |
DisclosureSEC source: 0001209191-23-003004 · doc5.xml · nonDerivative · entry 1 MARKS LILLY · CIK 0001645735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,813 F1 · shares: Shares purchased pursuant to the Orthofix Medical Inc. Second Amended and Restated Stock Purchase Plan, as Amended (the "Stock Purchase Plan") for the plan period ended October 31, 2022. F2 · price: Pursuant to the terms of the Stock Purchase Plan, shares are purchased at 85% of the fair market value of the Orthofix stock on the first day of the plan period or, if lower, on the last day of the plan period. Accordingly, shares were purchased at $13.65 per share, or at 85% of the quoted market price of $16.06 on October 31, 2022. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 20:30 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 6,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035037 · doc4.xml · nonDerivative · entry 1 MARKS LILLY · CIK 0001645735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,520 F1 · shares: Deferred stock unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction, pursuant to Rule 16(b)-3(d) under the Securities Exchange Act of 1934, as amended. The award vest in full on the first anniversary of the grant date, June 6, 2022. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:31 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 4,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-042747 · doc4.xml · nonDerivative · entry 1 MARKS LILLY · CIK 0001645735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,573 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 21, 2021. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 22:02 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 4,588 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-035659 · doc4.xml · nonDerivative · entry 1 MARKS LILLY · CIK 0001645735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,794 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 8, 2020. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 21:58 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 3,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036910 · doc4.xml · nonDerivative · entry 1 MARKS LILLY · CIK 0001645735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,696 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The award vests in full on the first anniversary of the grant date, June 11, 2019. Read SEC document |
| July 17, 2018 Filed Jul 17, 2018 23:01 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 2,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-042916 · doc4.xml · nonDerivative · entry 1 MARKS LILLY · CIK 0001645735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,929 F1 · shares: Deferred Stock Unit award granted on July 2, 2018, subject to shareholder approval, which was obtained on July 17, 2018, and is subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 2, 2019. Read SEC document |
| July 03, 2017 Filed Jul 10, 2017 21:59 UTC | Orthofix Medical Inc. OFIX · Entity 1975 | GrantCommon Stock | 3,579 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044654 · doc4.xml · nonDerivative · entry 1 MARKS LILLY · CIK 0001645735 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,029 F1 · shares: Deferred Stock Unit award subject to deferred distribution after termination of service as a director of the Issuer, an exempt transaction pursuant to Rule 16b-3(d) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These awards vest in full on July 3, 2018. Vested shares of common stock will be delivered to the reporting person within 45 days after termination of service as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.